WBR0790: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}}
|QuestionAuthor={{SSK}} (Reviewed by Serge Korjian)
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Pharmacology
|MainCategory=Pharmacology
Line 8: Line 8:
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|SubCategory=Infectious Disease
|SubCategory=Infectious Disease
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|MainCategory=Pharmacology
Line 20: Line 21:
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|SubCategory=Infectious Disease
|SubCategory=Infectious Disease
|Prompt=A 52 year old man previously diagnosed with AIDS with a recent CD4 count of 34 presents to the HIV clinic for 2 weeks of slowly decreasing visual acuity. Concerned about the possibility of an infection given the patient’s CD4 count, the infectious disease fellow admits him for treatment. One week into the treatment the patient starts experiencing anxiety, muscle twitching, and tremulousness. Blood tests reveal significant hypomagnesemia, hypocalcemia, and hypophosphatemia. Which of the following agents was the patient started on?
|Prompt=A 52-year-old man previously diagnosed with AIDS with a recent CD4 count of 28 presents to the HIV clinic for 2 weeks of slowly decreasing visual acuity. Concerned about the possibility of infection, the infectious disease fellow admits him for treatment. One week into the treatment the patient starts experiencing anxiety, muscle twitching, and tremulousness. Blood tests reveal significant hypomagnesemia, hypocalcemia, and hypophosphatemia. Which of the following agents was the patient started on?
|Explanation=Foscarnet is an antiviral pyrophosphate analog that is mostly used in patients with moderate to severe herpes virus and CMV infections. It acts by binding near the pyrophosphate-binding site on the viral DNA polymerase, blocking the exchange of pyrophosphate from deoxynucleotide triphosphates and leading to DNA chain termination. Forscarnet does not need any modification to be functional compared to other antivirals like acyclovir and ganciclovir. A rare but serious complication of foscarnet administration is electrolyte imbalance particularly hypomagnesemia, hypocalcemia, and hypophosphatemia. It is common to observe a decrease in PTH levels as well.  
|Explanation=Foscarnet is an antiviral pyrophosphate analog that is predominantly used in patients with moderate to severe herpes virus and CMV infections. The patient is this scenario is presenting with decreasing visual acquity in the context of a very low CD4 count raising the suspicion for CMV retinitis. Foscarnet acts by binding proximally to the pyrophosphate-binding site on the viral DNA polymerase, blocking the exchange of pyrophosphate from deoxynucleotide triphosphates and leading to DNA chain termination. Forscarnet does not require any ''in vivo'' modification to be functional compared to other antivirals like acyclovir and ganciclovir. A rare but serious complication of foscarnet administration is electrolyte imbalance particularly hypomagnesemia, hypocalcemia, and hypophosphatemia. It is common to observe a decrease in PTH levels as well.  


This patient has the typical presentation CMV retinitis which he is at high risk for given his CD4 count. Any patient with a CD4<50 and visual disturbances should be worked-up for CMV retinitis.
This patient has the typical presentation CMV retinitis which he is at high risk for given his CD4 count. Any patient with a CD4<50 and visual disturbances should be worked-up for CMV retinitis.
Line 33: Line 34:
Buckley MS, Leblanc JM, Cawley MJ. Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S253-64.
Buckley MS, Leblanc JM, Cawley MJ. Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S253-64.
|AnswerA=Acyclovir
|AnswerA=Acyclovir
|AnswerAExp=Acyclovir is not active against CMV so it should never be used in suspected CMV retinitis. Acyclovir is not known to cause electrolyte imbalances.
|AnswerAExp=Acyclovir is not active against CMV so it should never be used in suspected CMV retinitis. Acyclovir is not known to cause electrolyte imbalances.
|AnswerB=Valacyclovir
|AnswerB=Valacyclovir
|AnswerBExp=Valacyclovir is a prodrug of acyclovir that has a better bioavailability than acyclovir. It is not active against CMV. Valacyclovir is not known to cause electrolyte imbalances.
|AnswerBExp=Valacyclovir is a prodrug of acyclovir that has a better bioavailability than acyclovir. It is not active against CMV. Valacyclovir is not known to cause electrolyte imbalances.
|AnswerC=Amphotericin B
|AnswerC=Amphotericin B
|AnswerCExp=Amphotericin B is an antifungal that has no use in CMV retinitis. It is however known to cause elctrolyte imbalances especially with the initial doses.
|AnswerCExp=Amphotericin B is an antifungal that has no use in CMV retinitis. It is however known to cause elctrolyte imbalances especially with the initial doses.
|AnswerD=Cidofovir
|AnswerD=Cidofovir
|AnswerDExp=Cidofovir is another agent used in the treatment of resistant CMV. It is known to cause nephrotoxicity but does not usually cause electrolyte imbalances.
|AnswerDExp=Cidofovir is another agent used in the treatment of resistant CMV. It is known to cause nephrotoxicity but does not usually cause electrolyte imbalances.
|AnswerE=Foscarnet
|AnswerE=Foscarnet
|AnswerEExp=Foscarnet is used in the treatment of CMV retinitis and although not very common, can cuase electrolyte imbalances typically hypomagnesemia, hypocalcemia, and hypophosphatemia.
|AnswerEExp=Foscarnet is used in the treatment of CMV retinitis and although not very common, can cuase electrolyte imbalances typically hypomagnesemia, hypocalcemia, and hypophosphatemia.
|RightAnswer=E
|RightAnswer=E
|WBRKeyword=Foscarnet, Electrolyte imbalance
|WBRKeyword=Foscarnet, Electrolyte imbalance, CMV retinitis, Antivirals, Side Effects
|Approved=No
|Approved=Yes
}}
}}

Revision as of 17:44, 30 December 2014

 
Author [[PageAuthor::Serge Korjian M.D. (Reviewed by Serge Korjian)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pharmacology
Sub Category SubCategory::Infectious Disease
Prompt [[Prompt::A 52-year-old man previously diagnosed with AIDS with a recent CD4 count of 28 presents to the HIV clinic for 2 weeks of slowly decreasing visual acuity. Concerned about the possibility of infection, the infectious disease fellow admits him for treatment. One week into the treatment the patient starts experiencing anxiety, muscle twitching, and tremulousness. Blood tests reveal significant hypomagnesemia, hypocalcemia, and hypophosphatemia. Which of the following agents was the patient started on?]]
Answer A AnswerA::Acyclovir
Answer A Explanation AnswerAExp::Acyclovir is not active against CMV so it should never be used in suspected CMV retinitis. Acyclovir is not known to cause electrolyte imbalances.
Answer B AnswerB::Valacyclovir
Answer B Explanation AnswerBExp::Valacyclovir is a prodrug of acyclovir that has a better bioavailability than acyclovir. It is not active against CMV. Valacyclovir is not known to cause electrolyte imbalances.
Answer C AnswerC::Amphotericin B
Answer C Explanation AnswerCExp::Amphotericin B is an antifungal that has no use in CMV retinitis. It is however known to cause elctrolyte imbalances especially with the initial doses.
Answer D AnswerD::Cidofovir
Answer D Explanation AnswerDExp::Cidofovir is another agent used in the treatment of resistant CMV. It is known to cause nephrotoxicity but does not usually cause electrolyte imbalances.
Answer E AnswerE::Foscarnet
Answer E Explanation AnswerEExp::Foscarnet is used in the treatment of CMV retinitis and although not very common, can cuase electrolyte imbalances typically hypomagnesemia, hypocalcemia, and hypophosphatemia.
Right Answer RightAnswer::E
Explanation [[Explanation::Foscarnet is an antiviral pyrophosphate analog that is predominantly used in patients with moderate to severe herpes virus and CMV infections. The patient is this scenario is presenting with decreasing visual acquity in the context of a very low CD4 count raising the suspicion for CMV retinitis. Foscarnet acts by binding proximally to the pyrophosphate-binding site on the viral DNA polymerase, blocking the exchange of pyrophosphate from deoxynucleotide triphosphates and leading to DNA chain termination. Forscarnet does not require any in vivo modification to be functional compared to other antivirals like acyclovir and ganciclovir. A rare but serious complication of foscarnet administration is electrolyte imbalance particularly hypomagnesemia, hypocalcemia, and hypophosphatemia. It is common to observe a decrease in PTH levels as well.

This patient has the typical presentation CMV retinitis which he is at high risk for given his CD4 count. Any patient with a CD4<50 and visual disturbances should be worked-up for CMV retinitis.


Learning objective: A rare complication of foscarnet is electrolyte imbalance typically hypomagnesemia, hypocalcemia, and hypophosphatemia.


Reference:

Buckley MS, Leblanc JM, Cawley MJ. Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Crit Care Med. 2010;38(6 Suppl):S253-64.
Educational Objective:
References: ]]

Approved Approved::Yes
Keyword WBRKeyword::Foscarnet, WBRKeyword::Electrolyte imbalance, WBRKeyword::CMV retinitis, WBRKeyword::Antivirals, WBRKeyword::Side Effects
Linked Question Linked::
Order in Linked Questions LinkedOrder::